KR20120006513A - 신규 용매화물 결정 - Google Patents

신규 용매화물 결정 Download PDF

Info

Publication number
KR20120006513A
KR20120006513A KR1020117025160A KR20117025160A KR20120006513A KR 20120006513 A KR20120006513 A KR 20120006513A KR 1020117025160 A KR1020117025160 A KR 1020117025160A KR 20117025160 A KR20117025160 A KR 20117025160A KR 20120006513 A KR20120006513 A KR 20120006513A
Authority
KR
South Korea
Prior art keywords
acetone
crystal
solvent
crystals
water
Prior art date
Application number
KR1020117025160A
Other languages
English (en)
Korean (ko)
Inventor
히로시 기요타
히데아키 이시카와
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120006513(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Publication of KR20120006513A publication Critical patent/KR20120006513A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020117025160A 2009-04-28 2010-04-27 신규 용매화물 결정 KR20120006513A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009109160 2009-04-28
JPJP-P-2009-109160 2009-04-28

Publications (1)

Publication Number Publication Date
KR20120006513A true KR20120006513A (ko) 2012-01-18

Family

ID=43032159

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117025160A KR20120006513A (ko) 2009-04-28 2010-04-27 신규 용매화물 결정

Country Status (19)

Country Link
US (2) US8859600B2 (ru)
EP (1) EP2426127B1 (ru)
JP (2) JP5697593B2 (ru)
KR (1) KR20120006513A (ru)
CN (1) CN102414201B (ru)
AU (1) AU2010242635A1 (ru)
BR (1) BRPI1013336B1 (ru)
CA (1) CA2760031C (ru)
CO (1) CO6470817A2 (ru)
ES (1) ES2753874T3 (ru)
IL (1) IL215965A0 (ru)
MX (1) MX2011011540A (ru)
MY (1) MY158090A (ru)
NZ (1) NZ596326A (ru)
RU (1) RU2563631C2 (ru)
SG (2) SG175296A1 (ru)
TW (1) TWI464162B (ru)
WO (1) WO2010126014A1 (ru)
ZA (1) ZA201107813B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021224A2 (en) * 2009-08-19 2011-02-24 Msn Laboratories Limited Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate
CN103214469B (zh) * 2013-04-29 2014-12-10 孙威 一种奥美沙坦酯化合物及其制备方法
CN107474042A (zh) * 2017-09-07 2017-12-15 浙江华海致诚药业有限公司 一种三苯甲基奥美沙坦酯的晶型h
CN110082449B (zh) * 2019-05-24 2020-05-19 珠海润都制药股份有限公司 一种奥美沙坦酯中三苯基氯甲烷的检测方法
CN113105439A (zh) * 2021-04-15 2021-07-13 迪嘉药业集团有限公司 一种小粒度奥美沙坦酯的结晶制备方法
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0282519A (ja) 1988-09-19 1990-03-23 Sanyo Electric Co Ltd 固相エピタキシャル成長方法
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
JPH0753489A (ja) * 1993-06-11 1995-02-28 Sankyo Co Ltd ビフェニルカルボキサミド誘導体の製造法
JPH07121918A (ja) 1993-08-30 1995-05-12 Tdk Corp 光磁気記録媒体
JP3521304B2 (ja) 1996-03-21 2004-04-19 東洋化成工業株式会社 １−（テトラゾリルビフェニルメチル）イミダゾール誘導体の製造方法
JP3671266B2 (ja) 1996-03-21 2005-07-13 東洋化成工業株式会社 ５−置換テトラゾール類の製造方法
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
JP2004217542A (ja) 2003-01-10 2004-08-05 Fuji Photo Film Co Ltd ４，５−ジアルコキシカルボニルイミダゾールの製造方法
EP1784398A1 (en) 2004-09-02 2007-05-16 Teva Pharmaceutical Industries Ltd Purification of olmesartan medoxomil
JP4511550B2 (ja) 2004-09-02 2010-07-28 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの調製法
US20070054948A1 (en) 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
JP2006111586A (ja) 2004-10-15 2006-04-27 Nippon Petrochemicals Co Ltd 置換芳香族化合物の酸化方法
US7563814B2 (en) 2005-01-03 2009-07-21 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil with reduced levels of impurities
EA014026B1 (ru) 2005-07-29 2010-08-30 Крка, Товарна Здравил, Д.Д., Ново Место Способ получения олмесартан медоксомила
SI22092A (sl) 2005-07-29 2007-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo olmesartan medoksomila
WO2007047838A2 (en) * 2005-10-20 2007-04-26 Dr. Reddy's Laboratories Ltd. Process for preparing olmesartan medoxomil
CZ299902B6 (cs) 2005-10-27 2008-12-29 Zentiva, A. S Zpusob odstranování trifenylmethanové chránicí skupiny u prekurzoru antihypertenzních léciv
US8048904B2 (en) 2006-06-19 2011-11-01 Matrix Laboratories Ltd. Process for the preparation of olmesartan medoxomil
ITMI20061848A1 (it) 2006-09-27 2008-03-28 Dipharma Spa Procedimento per la preparazione di composti feniltetrazolici
WO2008043996A2 (en) * 2006-10-09 2008-04-17 Cipla Limited Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
EP2036904A1 (en) 2007-08-08 2009-03-18 LEK Pharmaceuticals D.D. A process for the preparation of olmesartan medoxomil
CN101778843A (zh) * 2007-08-08 2010-07-14 力奇制药公司 制备奥美沙坦酯的方法
ES2540062T3 (es) 2008-06-09 2015-07-08 Daiichi Sankyo Company, Limited Procedimiento de producción de un compuesto de 1-bifenilmetilimidazol
WO2010026255A1 (en) 2008-09-05 2010-03-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for preparing olmesartan medoxomil intermediate
TWI539948B (zh) * 2009-04-28 2016-07-01 第一三共股份有限公司 奧美沙坦酯之製造方法
WO2011014611A2 (en) 2009-07-30 2011-02-03 Dr. Reddy's Laboratories Ltd. Preparation of olmesartan medoxomil
WO2012001694A1 (en) 2010-06-28 2012-01-05 Hetero Research Foundation Process for olmesartan medoxomil

Also Published As

Publication number Publication date
WO2010126014A1 (ja) 2010-11-04
US20120059172A1 (en) 2012-03-08
MX2011011540A (es) 2012-04-30
EP2426127A1 (en) 2012-03-07
JP2015071647A (ja) 2015-04-16
CN102414201A (zh) 2012-04-11
TW201043616A (en) 2010-12-16
JP5697593B2 (ja) 2015-04-08
EP2426127B1 (en) 2019-09-04
AU2010242635A2 (en) 2014-08-07
BRPI1013336A2 (pt) 2016-03-29
RU2563631C2 (ru) 2015-09-20
CO6470817A2 (es) 2012-06-29
IL215965A0 (en) 2012-01-31
SG10201501131SA (en) 2015-04-29
ES2753874T3 (es) 2020-04-14
SG175296A1 (en) 2011-11-28
EP2426127A4 (en) 2012-10-03
JP5944539B2 (ja) 2016-07-05
TWI464162B (zh) 2014-12-11
MY158090A (en) 2016-08-30
RU2011148101A (ru) 2013-06-10
US8859600B2 (en) 2014-10-14
ZA201107813B (en) 2012-07-25
BRPI1013336B1 (pt) 2020-02-04
CN102414201B (zh) 2015-10-14
CA2760031C (en) 2015-03-10
JPWO2010126014A1 (ja) 2012-11-01
NZ596326A (en) 2014-02-28
US20160102079A1 (en) 2016-04-14
CA2760031A1 (en) 2010-11-04
AU2010242635A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
JP5944539B2 (ja) 新規溶媒和物結晶およびその製造方法
US7563814B2 (en) Olmesartan medoxomil with reduced levels of impurities
US20060258727A1 (en) Olmesartan medoxomil with reduced levels of impurities
KR101545068B1 (ko) Ｃｄｄｏ 에틸 에스테르의 다형체 및 이의 용도
TWI539948B (zh) 奧美沙坦酯之製造方法
EP1590343B1 (en) Synthesis of 2-butyl-3-(2' -(1-trityl-1h-tetrazol-5-yl)biphen yl-4-yl)-1,3-diazaspiro-4,4 -nonene-4-one
KR101523264B1 (ko) 올메사탄 메독소밀의 유연물질의 제조방법
KR101257272B1 (ko) 탈보호화 반응을 이용한 고혈압 치료용 비페닐테트라졸 화합물의 제조방법

Legal Events

Date Code Title Description
AMND Amendment
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment